Skip Navigation


Annals of Oncology Advance Access originally published online on September 8, 2005
Annals of Oncology 2005 16(10):1709; doi:10.1093/annonc/mdi325
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/10/1709    most recent
mdi325v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Normanno, N.
Right arrow Articles by Menard, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Normanno, N.
Right arrow Articles by Menard, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Letter to the Editor

Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?

The first 10% of the full text of this article appears below.

We have previously demonstrated that combined treatment of breast cancer cells that co-express epidermal growth factor receptor (EGFR) and ErbB-2 with the EGFR tyrosine kinase inhibitor (TKI) gefitinib plus trastuzumab results in a synergistic antitumor effect [1Go]. Similar findings have been obtained by independent research groups [2Go]. Following these results, . . . [Full Text of this Article]

N. Normanno1,*, M. Campiglio2, F. Perrone3, A. De Luca1 and S. Menard2

1 Cell Biology and Preclinical Models Unit and 3 Clinical Trials Unit, INT-Fondazione Pascale, 80131 Naples; 2 Molecular Targeting Unit, Istituto Tumori Milano, 20133 Milan, Italy

* E-mail: nicnorm@yahoo.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney
Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
Cancer Res., March 1, 2008; 68(5): 1471 - 1477.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G Valabrega, F Montemurro, and M Aglietta
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Ann. Onc., June 1, 2007; 18(6): 977 - 984.
[Abstract] [Full Text] [PDF]